Floatz logo

MODIFIED VACCINIA VIRUS ANKARA-5T4 ANTIGEN

Peritoneal Cancer

University College, LondonvaccinePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
81/ 100

Competitive context

37 Active assets in the Peritoneal Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Peking University
Phase 2BB
Docetaxel
University of Pittsburgh
Phase 2BB
FLUOROURACILUM
City of Hope Medical Center
Phase 3BB
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Irinotecan
City of Hope Medical Center
Phase 3BB

View all 50 →

Same molecule, other indications

MODIFIED VACCINIA VIRUS ANKARA-5T4 ANTIGEN is also rated in:

renal cell carcinomaDormant
B
Indicative ·
62 / 100
View asset →
clear cell renal carcinomaDormant
B
Indicative ·
60 / 100
View asset →
prostate neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →